Daily versus cyclic PTH combined with alendronate versus alendronate alone for treatment of osteoporosis.

被引：0
|
作者：
Cosman, F
Nieves, JW
Luckey, MM
Zion, M
Woelfert, L
Lindsay, R
机构：
[1] St Barnabus Hosp, Livingston, NJ USA
[2] Helen Hayes Hosp, Clin Res Ctr, W Haverstraw, NY USA
[3] Helen Hayes Hosp, Reg Bone Ctr, W Haverstraw, NY USA
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2003年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S32 / S32
页数：1
相关论文
共 50 条
  • [1] Combined calcitriol-alendronate treatment in osteoporosis.
    Frediani, B
    Porfidio, G
    Bisogno, S
    Ronconi, S
    Corrado, A
    Marcolongo, R
    ARTHRITIS AND RHEUMATISM, 1997, 40 (09): : 632 - 632
  • [2] Treatment with etidronate or alendronate in postmenopausal osteoporosis.
    Lissens, MA
    JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 : S277 - S277
  • [3] Alendronate in the prevention of osteoporosis.
    Sambrook, PN
    Rodriguez, JP
    Wasnich, RD
    Luckey, MM
    Kaur, A
    Lombardi, A
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S207 - S207
  • [4] Greater preference and better satisfaction with alendronate 70 mg weekly versus alendronate 10 daily for the treatment of postmenopausal osteoporosis
    Sawicki, Andrzej Z.
    MENOPAUSE REVIEW-PRZEGLAD MENOPAUZALNY, 2005, 4 (06): : 22 - 28
  • [5] EFFECTS OF A COMBINED TREATMENT WITH ALFACALCIDOL AND ALENDRONATE VERSUS TREATMENT WITH ALENDRONATE ALONE ON BONE MINERAL DENSITY AT LUMBAR SPINE AND TOTAL HIP IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS OR OSTEOPENIA
    Bock, O.
    Felsenberg, D.
    Boerst, H.
    Degner, C.
    Armbrecht, G.
    Schacht, E.
    Mazor, Z.
    Hashimoto, J.
    Martus, P.
    Runge, M.
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 : 76 - 77
  • [6] Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene
    Huang, Weng-Foung
    Tsai, Yi-Wen
    Wen, Yu-Wen
    Hsiao, Fei-Yuan
    Kuo, Ken N.
    Tsai, Chia-Rung
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2010, 17 (01): : 57 - 63
  • [7] BONE-TARGETING DELIVERY OF ALENDRONATE FOR THE TREATMENT OF OSTEOPOROSIS.
    Chen, Shen-Mao
    Zhao, Lingling
    Lee, Tung-Chun
    Liu, Chaozong
    TISSUE ENGINEERING PART A, 2022, 28 : S228 - S228
  • [8] Alendronate in the treatment of primary hyperparathyroid-related osteoporosis.
    Parker, CR
    Blackwell, PJ
    Hosking, DJ
    JOURNAL OF BONE AND MINERAL RESEARCH, 1998, 13 (09) : 1508 - 1508
  • [9] The effect of oral alendronate versus intravenous pamidronate on bone mineral density in patients with osteoporosis.
    Vis, M
    Bultink, I
    Dijkmans, B
    Lems, W
    JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 : S311 - S311
  • [10] PTH and bisphosphonates in the treatment of osteoporosis: The PTH and alendronate (PaTH) trial.
    Black, DM
    Rosen, C
    Greenspan, S
    Ensrud, K
    Bilezikian, J
    McGowan, J
    JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 : S287 - S287
12345